期刊
CHEST
卷 161, 期 1, 页码 169-178出版社
ELSEVIER
DOI: 10.1016/j.chest.2021.08.041
关键词
ARDS; COVID-19; lung transplantation; pulmonary fibrosis
The COVID-19 pandemic has caused acute lung injury in millions of individuals worldwide, some of whom may require lung transplantation for severe lung injury or post-COVID fibrosis. Lung transplantation after COVID-19 infection presents unique challenges, including difficulties in evaluation and education, deconditioning, and infectious concerns. Transplant physicians must carefully consider the risks and benefits of lung transplantation in post-COVID fibrosis patients compared to other lung diseases.
The COVID-19 pandemic has caused acute lung injury in millions of individuals worldwide. Some patients develop COVID-related acute respiratory distress syndrome (CARDS) and cannot be liberated from mechanical ventilation. Others may develop post-COVID fibrosis, resulting in substantial disability and need for long-term supplemental oxygen. In both of these situations, treatment teams often inquire about the possibility of lung transplantation. In fact, lung transplantation has been successfully employed for both CARDS and post-COVID fibrosis in a limited number of patients worldwide. Lung transplantation after COVID infection presents a number of unique challenges that transplant programs must consider. In those with severe CARDS, the inability to conduct proper psychosocial evaluation and pretransplantation educa-tion, marked deconditioning from critical illness, and infectious concerns regarding viral reac-tivation are major hurdles. In those with post-COVID fibrosis, our limited knowledge about the natural history of recovery after COVID-19 infection is problematic. Increased knowledge of the likelihood and degree of recovery after COVID-19 acute lung injury is essential for appropriate decision-making with regard to transplantation. Transplant physicians must weigh the risks and benefits of lung transplantation differently in a post-COVID fibrosis patient who is likely to remain stable or gradually improve in comparison with a patient with a known progressive fibrosing interstitial lung disease (fILD). Clearly lung transplantation can be a life-saving therapeutic option for some patients with severe lung injury from COVID-19 infection. In this review, we discuss how lung transplant providers from a number of experienced centers approach lung transplantation for CARDS or post-COVID fibrosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据